"ADR Shares End Lower; Novo Nordisk Shares Trade Actively" on Tuesday at 5:29 p.m. EDT incorrectly said Novo Nordisk received a favorable view from a U.S. Food and Drug Administration advisory committee on its diabetes drug Saxenda. Rather, documents released ahead of the FDA Advisory Committee review suggested Saxenda is effective for weight loss.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novo Nordisk Charts.